JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265398

Human TPGS2 (L17) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TPGS2 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.

View Alternative Names

C18orf10, C18orf10 chromosome 18 open reading frame 10, Chromosome 18 open reading frame 10, DKFZP586M1523, HMFN0601, HsT3006, TPGS2_HUMAN, Tubulin polyglutamylase complex subunit 2

2 Images
Sanger Sequencing - Human TPGS2 (L17) knockout HeLa cell line (AB265398)
  • Sanger seq

Unknown

Sanger Sequencing - Human TPGS2 (L17) knockout HeLa cell line (AB265398)

Allele-1 : 1 bp deletion in exon 1.

Sanger Sequencing - Human TPGS2 (L17) knockout HeLa cell line (AB265398)
  • Sanger seq

Unknown

Sanger Sequencing - Human TPGS2 (L17) knockout HeLa cell line (AB265398)

Allele-2 : Insertion of the selection cassette in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265398-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265398 Human TPGS2 (L17) knockout HeLa cell line", "number":"AB265398-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265398-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265398 Human TPGS2 (L17) knockout HeLa cell line", "number":"AB265398-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TPGS2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

L17 also known as ribosomal protein L17 is an important component of the 60S subunit of the eukaryotic ribosome. It has a molecular mass of approximately 22 kDa. L17 is expressed in various tissues throughout the body with particularly high expression levels in rapidly-dividing cells. As a structural element of the large ribosomal subunit L17 plays a role in the core processes of protein synthesis.
Biological function summary

The function of protein L17 involves participation in the formation of the ribosome complex. It interacts with other ribosomal proteins and rRNA molecules to ensure the accurate assembly of the ribosome. This assembly allows the ribosomal machinery to facilitate efficient translation of mRNA into polypeptides which are subsequently folded into functional proteins essential for cellular functions and proliferation.

Pathways

The protein L17 engages with translation-related pathways notably the ribosomal biogenesis pathway and the mTOR signaling pathway. The mTOR pathway regulates cell growth and metabolism in response to nutrients stress and growth factors. As part of the ribosome L17 indirectly associates with proteins like RPL5 and RPL11 essential for ribosome biogenesis and function forming a link between ribosome assembly and cellular regulation.

Ribosomal protein L17 has implications in ribosomopathies such as Diamond-Blackfan Anemia which is characterized by impaired ribosome biogenesis and function. Mutations affecting L17 and its associated proteins such as RPL5 and RPL11 can disrupt normal ribosomal biogenesis leading to developmental abnormalities and increased susceptibility to specific cancers due to the imbalance in protein synthesis and cellular homeostasis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com